Comparative efficacy of thrombolytics in acute myocardial infarction: A systematic review

QJM: An International Journal of Medicine

Volumn 96, Issue 2, 2003, Pages 103-113

  Dundar, Y ^a   Hill, R ^a   Dickson, R ^a   Walley, T ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HEPARIN; RETEPLASE; STREPTOKINASE; TENECTEPLASE;

ACUTE HEART INFARCTION; ANAPHYLAXIS; ARTICLE; BLEEDING; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; EMBASE; HEART REINFARCTION; HUMAN; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SCISEARCH; STROKE;

EID: 0037292239     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hcg016     Document Type: Article

References (34)

1. Yusuf S, Collins R, Peto R, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985; 6:556-85.
2. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343:311-22.
3. Llevadot J, Giugliano R, Antman E. Bolus fibrinolytic therapy in acute myocardial infarction. JAMA 2001; 286:442-9.
4. Wilcox RG. Clinical trials in thrombolytic therapy: what do they tell us? INJECT 6-month outcomes data. Am J Cardiol 1996; 78:20-3.
5. Walley T, Dundar Y, Dickson R, Hill R. Superiority and equivalence in thrombolytic drugs: an interpretation. Q J Med 2003; 96:155-60.
6. Khan K, Ter Riet G, Glanville J, Sowdon A, Kleijnen J. Undertaking systematic reviews of research on effectiveness. CRD guidance for carrying out or commissioning reviews, 2nd edn. CRD Report 4. York, NHS Centre for Reviews and Dissemination (CRD), University of York, 2000.
7. GUSTO. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329:673-82.
8. Taylor GJ, Moses HW, Koester D, Colliver JA, Katholi RE, Dove JT, et al. A difference between front-loaded streptokinase and standard-dose recombinant tissue-type plasminogen activator in preserving left ventricular function after acute myocardial infarction (the Central Illinois Thrombolytic Therapy Study). Am J Cardiol 1993; 72:1010-14.
9. Cherng WJ, Chiang CW, Kuo CT, Lee CP, Lee YS. A comparison between intravenous streptokinase and tissue plasminogen activator with early intravenous heparin in acute myocardial infarction. Am Heart J 1992; 123:841-6.
10. Verstraete M, Bernard R, Bory M, Brower RW, Collen D, de Bono DP, et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet 1985; 1:842-7.
11. Feruglio GA, Lotto A, Rovelli F, Solinas P, Tavazzi L, Tognoni G, et al. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336:65-71.
12. Van de Werf F, Wilcox RG, Barbash GI, Diaz R, Franzosi MG, Hampton JR, et al. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990; 336:71-5.
13. Hunt D, Varigos J, Dienstl F, Lechleitner P, Mauel C, Dienstl A, et al. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339:753-770.
14. Grines CL, Nissen SE, Booth DC, Gurley JC, Chelliah N, Wolf R, et al. A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Circulation 1991; 84:540-9.
15. Magnani B. Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol 1989; 13:19-26.
16. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76:142-54.
17. White HD, Rivers JT, Maslowski AH, Ormiston JA, Takayama M, Hart HH, et al. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med 1989; 320:817-21.
18. Van de Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, Barbash G, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354:716-22.
19. Topol EJ, Califf R, Ohman E, Skene A, Wilcox R, Grinfeld L, et al. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337:1118-23.
20. Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalbfleisch JM, et al. Randomized comparison of coronary thrombolysis achieved with double- bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996; 94:891-8.
21. Hampton JR, Schroder R, Wilcox RG, Skene AM, Meyer-Sabellek W, Heikkila J, et al. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995; 346:329-36.
22. Ohman E, Harrington R, Cannon CP, Agnelli G, Cairns J, Kennedy JW. Intravenous thrombolysis in acute myocardial infarction. Chest 2001; 119(Suppl.):253-77S.
23. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, et al. ACC/AHA guidelines for the management of patients with acute myocardial intarction: update - a report. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction), 1999; available at www.acc.org.
24. Mulrow C. Rationale for systematic reviews. In: Chalmers I, Altman D, eds. Systematic Reviews. London, BMJ 1995.
25. Lau J, Antman E, Jiimenez-Silva J, Kupelnick B, Mosteller F, Chambers T. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327:248-54.
26. GISSI. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986; 1:397-402.
27. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized Trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS2. J Am Coll Cardiol 1988; 12:3-13A.
28. Teo K, Yusef S, Collins R, Held P, Peto R. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. Br Med J 1991; 303:1499-505.
29. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345:669-85.
30. Yusuf S, Flather M. Magnesium in acute myocardial infarction. Br Med J 1995; 310:751-2.
31. Yusuf S, Collins R. Peto R. Why do we need some large, simple randomized trials? Stat Med 1984; 3:409-22.
32. Thompson S, Pocock S. Can meta-analyses be trusted? Lancet 1991; 338:1127-30.
33. Egger M, Smith G, Sterne J. Uses and abuses of meta-analysis. Clin Med 2001; 1:478-84.
34. Collins R, Peto R, Parish S, Sleight P. ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials. Am J Cardiol 1993; 71:1127-30.